Page 4 - Indian Pharma

Rising rupee another risk for Indian pharma

Pricing pressure and regulatory issues are not the only thing worrying executives of Indian pharmaceuticals' companies. Weakening of the dollar versus the rupee in the first four months of this calendar year is adding to the concerns; it might impact their earnings by five or six per cent. An appreciation in the rupee versus the dollar means every one of the latter yields less of the former, whereas a lot of the costs are denominated in rupees.Dr Reddy's Laboratories (DRL), Lupin and Sun Pharmaceutical earn close to half their revenue from the US market. DRL has the highest foreign exposure among large-cap stocks and earns 85 per cent of its revenue from abroad (53 per cent from North America); the rest is from India. Cipla, which earns 40 per cent of revenue from within India, would see the least impact from rupee appreciation; its US sales account for 18 per cent of the revenue. On a year-to-date basis (from January till this Thursday), the rupee has gained 5.45 per cent against ...

Quality culture: A big test for Indian pharma

Once a culture that fosters high standards is in place, the sector will truly become world class

Indian pharma pads up to fight Republican border tax

Experts claim border adjustment tax would hurt profits, increase healthcare costs

Changes in US put Indian pharma's R&D to test

With medicines going off patent over next 3 yrs, pharma majors have stepped up spending on research

Pricing pressure in US to take sheen off pharma

Torrent, Dr Reddy's, and Sun Pharmaceutical could see higher price erosion of existing portfolio